DOCSLIB.ORG

Comment Letter

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

July 23, 2008 Subject: Follow-up on July 22 Meeting Dr. Sirri et al.: I thank you for meeting with Ken Salomon, John Welborn and me yesterday afternoon to discuss Reg SHO, naked short selling and the SEC's recent emergency order. As a follow-up, I want to emphasize the following points: 1. OSTK continues to believe that it is critical that the SEC extend the pre-borrow requirement of the emergency order to the entire market, not just the 19 select companies. OSTK requests that the SEC promptly undertake swift rulemaking so that this protection applies fairly across the market. 2. OSTK continues to support the prompt and full elimination of the option market maker exception, an exception that swallows up the good intentions of Reg SHO. During yesterday's meeting, we discussed the relationship between the markets for equities and their corresponding derivatives (including listed options). You stated that options market makers enjoy an exception from the Reg SHO requirement that they locate and/or deliver shares when hedging against options positions. I am not sure that I would read Reg SHO to say that. However, under your theory, if an options market maker sells a put with a 6- month expiration, then that same market maker has the legal right to naked short and fail to deliver an equivalent amount of the underlying equity (leaving the option market maker "delta neutral”) for six months. This exception is unnecessary and open to abuse/manipulation, particularly with the married puts that often occur in Reg SHO threshold securities. Further, OSTK does not believe that such a transaction is “net neutral"—that is, that this introduces no additional long or short pressure into the market for an issue, as a whole. That would be true if the options market maker entered into a legitimate short sale arrangement to borrow shares for the duration of the options contract. The act of naked shorting and failing to deliver in perpetuity, however, creates a "net change" in the aggregate “risk profile” of an issue (that is, the sum of all long/short positions, both in the derivatives space and in the underlying equity). Furthermore, the change in the gross sum of tradable securities entitlements in the equity market can drive the price below its equilibrium level, both in the short run and long run. In addition, the option market maker exception has the added effect of depressing stock loan rebate rates, as the options market has become a surrogate for the stock loan market. The option market maker exception is not only unnecessary, it is tool used for market distortion and manipulation. 3. OSTK applauds the SEC for beginning to disclose the daily volume of failures-to- deliver on a company by company basis. This is useful information that investors need to be able to access. OSTK urges the SEC to disclose (or perhaps better yet require either the exchanges or the DTCC to disclose) this information on a much more timely basis. The current lagged disclosure is as much as five months stale. At the very least, this failure-to-deliver data should be available to investors at least as frequently as the legitimate short interest data (which the exchanges release twice a month). 4. OSTK (along with many others) has long advocated including a pre-borrow requirement in Reg SHO. Yesterday you asked whether in a world where shares are always delivered, is such a pre-borrow requirement necessary. Assuming such world, OSTK believes the answer is "no" -- with several caveats: o Without strict and constant surveillance and regular and meaningful enforcement and penalties to ensure delivery, such a world is hard to imagine. o There would need to be no exceptions to the delivery requirement. o A pre-borrow requirement focuses on the front end of the trade and would ensure that no trade would result in a failure-to-deliver; a hard delivery requirement focuses on the back end of the trade and creates a period ripe for fraud. I suspect this is why theatres require patrons to present a ticket prior to entering the show, rather than allow them to watch the show and deliver a ticket five days later. o A hard delivery requirement still allows for an intra-period raid (the period would be a day if the hard delivery period was T+1 or a week if the hard delivery requirement was T+5). A trader (day trader, market maker, etc.) could raid a stock on naked short sales and cover under the panic sell that day. Without a pre-borrow requirement, a naked short selling trader never engages in a borrow so long as he covers during the required period. Having no pre-borrow allows the trader to sell as many shares as he likes, so long as he covers within the hard delivery period. There is a lot that can be masked by such trading activities, especially by hedge funds with the financial firepower to use fast trading technique to create the panic selling into a profitable cover. As the SEC considers the differences between a pre-borrow requirement and a hard delivery requirement, OSTK suggests that it consider the emerging technology (e.g., the Lendex platform) that may allow for maximum liquidity in a pre-borrow world. 5. Attached is a spreadsheet showing the $8.5b mark-to-market value of all of the failures-to-deliver that occurred with in the DTCC on March 31, 2008 (the most recent date for which failure-to-deliver data is available to the public). Companies listed on the Reg SHO threshold list make up $6.1b (72.5%) of the value. These numbers do not include failures-to-deliver occurring outside the DTCC. In addition, OSTK believes that the mark-to-market calculation is an overly conservative way to calculate the effect of the failures-to-deliver because those creating the failures-to-deliver would likely be unable to cover them at the market prices -- especially in stocks where the failures-to-deliver are a large part of (or exceed) the float. <<2008.03.31 (SEC) Total FTD Value.pdf>> 6. OSTK urges the SEC to expand the purview of Reg SHO to include transactions that occur outside the DTCC. As the SEC looks to improve Reg SHO, it makes sense to expand its purview to all trades. Otherwise, those that use Reg SHO's current loopholes to distort and manipulate the market will just move their abusive practices to ex-clearing transactions. Again, I thank you for taking yesterday's meeting and for your thoughtful consideration of the above points. Regards, Jonathan Jonathan Johnson Overstock.com, Inc. Mark-to-Market Value of FTDs on March 31, 2008 THRESHOLD TOTAL THRESHOLD SETTLEMENT TRADE SYMBOL DESCRIPTION FTDs PRICE FTDs*PRICE SECURITY? DAYS DATE DATE TOTAL:$ 8,475,914,767.63 TOTAL (SHO STOCKS ONLY): $ 6,144,891,554.23 1 A AGILENT TECHNOLOGIES, INC N 3/31/2008 192,480 3/31/2008 29.83 $ 5,741,678.40 2 AA ALCOA INC N 3/31/2008 586,593 3/31/2008 36.06 $ 21,152,543.58 3 AACC ASSET ACCEP CAP CORP N 3/31/2008 126,922 3/31/2008 9.63 $ 1,222,258.86 4 AACS AMERICAN COMMERCE SLTS INC N 3/31/2008 27,961 3/31/2008 0.01 $ 139.81 5 AAGH Asia Global Holdings Corp. Com N 3/31/2008 68,029 3/31/2008 0.10 $ 6,462.76 6 AANI AMEDIA NETWORKS INC Y 131 3/31/2008 101,635 3/31/2008 0.00 $ 71.14 7 AAPL APPLE INC COM STK N 3/31/2008 252,703 3/31/2008 143.50 $ 36,262,880.50 8 AAUK ANGLO AMER PLC NEW ADR UK Y 28 3/31/2008 26,748 3/31/2008 29.77 $ 796,287.96 9 ABA Alabama Power Company Sr Nt Se N 3/31/2008 15,820 3/31/2008 26.74 $ 423,026.80 10 ABD ACCO BRANDS CORPORATION N 3/31/2008 48,175 3/31/2008 13.57 $ 653,734.75 11 ABDS Allegro Biodiesel Corporation N 3/31/2008 11,927 3/31/2008 0.09 $ 1,073.43 12 ABFS ARKANSAS BEST CORP (DEL) Y 7 3/31/2008 76,112 3/31/2008 31.86 $ 2,424,928.32 13 ABH ABITIBIBOWATER, INC. Y 138 3/31/2008 1,359,481 3/31/2008 12.91 $ 17,550,899.71 14 ABI APPLERA CP-APPLIED BIOSYSTEMS N 3/31/2008 13,893 3/31/2008 32.86 $ 456,523.98 15 ABK AMBAC FINANCIAL GROUP INC. Y 75 3/31/2008 72,154 3/31/2008 5.75 $ 414,885.50 16 ABMBF ABCOURT MINES INC CL-B (F) N 3/31/2008 34,200 3/31/2008 0.42 $ 14,364.00 17 ABMD ABIOMED INC N 3/31/2008 39,068 3/31/2008 13.14 $ 513,353.52 18 ABN ABN AMRO HOLD N.V. ADS(1 ORD) Y 21 3/31/2008 10,602 3/31/2008 59.90 $ 635,059.80 19 ABNAF CONSOLIDATED ABADDON RES INC N 3/31/2008 42,000 3/31/2008 0.18 $ 7,518.00 20 ABNPRF ABN AMRO HLDG N.V. CAP FDG TR N 3/31/2008 13,984 3/31/2008 22.34 $ 312,402.56 21 ABPI ACCENTIA BIOPHARMACUETICALS IN Y 36 3/31/2008 486,544 3/31/2008 1.11 $ 540,063.84 22 ABR ARBOR REALTY TRUST INC Y 80 3/31/2008 130,034 3/31/2008 15.08 $ 1,960,912.72 23 ABTXQ AGRIBIOTECH INC N 3/31/2008 24,412 3/31/2008 - $ - 24 ABVG ABV GOLD INC COM STK Y 72 3/31/2008 1,261,200 3/31/2008 0.01 $ 7,567.20 25 ABWG A.B.
Recommended publications
  • Neural Networks

    Neural Networks

    AIAI andand thethe NetNet •• Buyer’sBuyer’s GuideGuide 19.1 Where Intelligent Technology Meets the Real World www.pcai.com IntelligentIntelligent Applications Applications TThehe ModernModern RoboticRobotic Also:Also: “Movement”“Movement” Agents, Business Applications, TThehe StateState ofof AIAI Today:Today: TheThe Business Intelligence, WWeb:eb: AI’sAI’s NewNew PlaygroundPlayground Computational Intelligence, Data Analysis & Mining, Robotics:Robotics: RobotsRobots ThatThat Intelligent Applications, Intelligent Tools, MimicMimic AnimalsAnimals Intelligent Tutoring, Intelligent Web Searching, TThehe NationalNational ScienceScience Neural Networks, Foundation:Foundation: EncouragingEncouraging Robotics, tthehe ResearchersResearchers ofof Speech Recognition, TTomorrowomorrow Web Based Expert Systems, Plus:Plus: AIAI andand thethe Net,Net, Training, Bookzone,Bookzone, Buyer’sBuyer’s Guide,Guide, AI Conferences, ProductProduct UUpdatespdates and more! PC AI 2 19.1 Quantities Limited Buy PC AI Back Issues 1995 1999 A Great Resource 9 #1 Intelligent Tools 13 #1 Intelligent Tools & Languages 9 #2 Fuzzy Logic / Neural Networks (Knowledge Verification) for AI Research 9 #3 Object Oriented Development 13 #2 Rule and Object Oriented 9 #4 Knowledge-Based Systems Development (Data Mining) $8.00/Issue - US 9 #5 AI Languages 13 #3 Neural Nets & Fuzzy Logic (For Us and Canadian and 9 #6 Business Applications (Searching) Foreign Postage 13 #4 Knowledge-Based Systems contact PC AI or visit the 1996 (Fuzzy Logic) 10 #1 Intelligent Applications PC AI web site) 13 #5 Data Mining (Simulation and 10 #2 Object Oriented Development Modeling) Order online at 10 #3 Neural Networks / Fuzzy Logic 13 #6 Business Applications www.pcai.com 10 #4 Knowledge-Based Systems (Machine Learning) Total amount enclosed 10 #5 Genetic Algorithm & Modeling 10 #6 Business Applications 2000 $____________.
  • Chicago Board Options Exchange Annual Report 2001

    Chicago Board Options Exchange Annual Report 2001

    01 Chicago Board Options Exchange Annual Report 2001 cv2 CBOE ‘01 01010101010101010 01010101010101010 01010101010101010 01010101010101010 01010101010101010 CBOE is the largest and 01010101010101010most successful options 01010101010101010marketplace in the world. 01010101010101010 01010101010101010 01010101010101010 01010101010101010 01010101010101010 01010101010101010ifc1 CBOE ‘01 ONE HAS OPPORTUNITIES The NUMBER ONE Options Exchange provides customers with a wide selection of products to achieve their unique investment goals. ONE HAS RESPONSIBILITIES The NUMBER ONE Options Exchange is responsible for representing the interests of its members and customers. Whether testifying before Congress, commenting on proposed legislation or working with the Securities and Exchange Commission on finalizing regulations, the CBOE weighs in on behalf of options users everywhere. As an advocate for informed investing, CBOE offers a wide array of educational vehicles, all targeted at educating investors about the use of options as an effective risk management tool. ONE HAS RESOURCES The NUMBER ONE Options Exchange offers a wide variety of resources beginning with a large community of traders who are the most experienced, highly-skilled, well-capitalized liquidity providers in the options arena. In addition, CBOE has a unique, sophisticated hybrid trading floor that facilitates efficient trading. 01 CBOE ‘01 2 CBOE ‘01 “ TO BE THE LEADING MARKETPLACE FOR FINANCIAL DERIVATIVE PRODUCTS, WITH FAIR AND EFFICIENT MARKETS CHARACTERIZED BY DEPTH, LIQUIDITY AND BEST EXECUTION OF PARTICIPANT ORDERS.” CBOE MISSION LETTER FROM THE OFFICE OF THE CHAIRMAN Unprecedented challenges and a need for strategic agility characterized a positive but demanding year in the overall options marketplace. The Chicago Board Options Exchange ® (CBOE®) enjoyed a record-breaking fiscal year, with a 2.2% growth in contracts traded when compared to Fiscal Year 2000, also a record-breaker.
  • Intel Corporation 2000 Annual Report

    Intel Corporation 2000 Annual Report

    silicon is in 2000 Annual Report i n t e l .c o m i n t c . c o m Intel facts and figures Net revenues Diluted earnings per share Dollars in billions Dollars, adjusted for stock splits 35 1.6 33.7 1.51 30 29.4 1.2 26.3 25 25.1 Intel revenues 1.05 20.8 20 grew 15% in 2000, 0.97 0.86 0.8 giving us our 14th 16.2 15 0.73 consecutive year of 11.5 10 0.50 0.4 8.8 revenue growth. 0.33 0.33 5.8 5 4.8 0.12 0.16 0 0 91 92 93 94 95 9697 98 99 00 91 92 93 94 95 9697 98 99 00 Geographic breakdown of 2000 revenues Return on average stockholders’ equity Percent Percent 100 40 38.4 35.5 35.6 33.3 North America 41% Intel has 30 75 30.2 experienced strong 27.3 28.4 26.2 international growth, 21.6 20 50 with 59% of revenues 20.4 Asia-Pacific 26% outside North America in 2000. 10 25 Europe 24% 0 Japan 9% 91 92 93 94 95 9697 98 99 00 0 Capital additions to property, Stock price trading ranges by fiscal year plant and equipment † Dollars, adjusted for stock splits Dollars in millions 75 8,000 Capital invest- 6,674 ments reflect Intel’s 6,000 50 commitment to building leading-edge manu- 4,501 4,000 4,032 facturing capacity for 3,550 3,403 25 3,024 state-of-the-art 2,441 2,000 silicon products.
  • Merger Proposed à Your Vote Is Very Important

    Merger Proposed à Your Vote Is Very Important

    MERGER PROPOSED Ì YOUR VOTE IS VERY IMPORTANT We are pleased to report that the boards of directors of Synopsys, Inc. and Avant! Corporation have each unanimously approved a merger involving our two companies. Before we can complete the merger, we must obtain the approval of our companies' stockholders. We are sending you this joint proxy statement/prospectus to ask you to vote in favor of the merger and related matters. In the merger, Avant! will merge with and into a subsidiary of Synopsys and will become a wholly- owned subsidiary of Synopsys, and Avant! stockholders will be entitled to receive 0.371 of a Synopsys common share in exchange for each of their Avant! common shares. Each outstanding Synopsys common share will remain unchanged in the merger. We estimate that in this merger Synopsys will issue approximately 16.8 million Synopsys common shares. Synopsys common shares trade on the Nasdaq National Market under the symbol ""SNPS.'' Avant! will hold a special meeting of its stockholders to consider and vote on the merger proposal. Synopsys will, at its annual meeting, consider and vote on the approval of the issuance of Synopsys common shares in the merger as well as vote to elect directors and ratify the appointment of independent auditors. Completion of the merger requires Avant! stockholder approval of the merger proposal and Synopsys stockholder approval of the issuance of Synopsys common shares in the merger. YOUR VOTE IS VERY IMPORTANT. Whether or not you plan to attend your stockholder meeting, please take the time to vote by completing the enclosed proxy card and mailing it to us.
  • United States Securities and Exchange Commission Form

    United States Securities and Exchange Commission Form

    QuickLinks -- Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ý Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 29, 2001. o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number 0-6217 INTEL CORPORATION (Exact name of registrant as specified in its charter) Delaware 94-1672743 (State or other jurisdiction of (I.R.S. Employer Identification No.) incorporation or organization) 2200 Mission College Boulevard, Santa Clara, California, 95052-8119 (Address of Principal Executive Offices, Zip Code) Registrant's telephone number, including area code (408) 765-8080 Securities registered pursuant to Section 12(b) of the Act: None Securities registered pursuant to Section 12(g) of the Act: Common stock, $0.001 par value Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No o Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.
  • Installation and Administration Guide

    Installation and Administration Guide

    Parametric Technology Corporation Schools Edition ® ® Pro/ENGINEER Wildfire 3.0 Installation and Administration Guide May 2006 Copyright © 2006 Parametric Technology Corporation. All Rights Reserved. User and training documentation from Parametric Technology Corporation and its subsidiary companies (PTC) is subject to the copyright laws of the United States and other countries and is provided under a license agreement that restricts copying, disclosure, and use of such documentation. PTC hereby grants to the licensed user the right to make copies in printed form of this documentation if provided on software media, but only for internal/personal use and in accordance with the license agreement under which the applicable software is licensed. Any copy made shall include the PTC copyright notice and any other proprietary notice provided by PTC. This documentation may not be disclosed, transferred, modified, or reduced to any form, including electronic media, or transmitted or made publicly available by any means without the prior written consent of PTC and no authorization is granted to make copies for such purposes. Information described herein is furnished for general information only, is subject to change without notice, and should not be construed as a warranty or commitment by PTC. PTC assumes no responsibility or liability for any errors or inaccuracies that may appear in this document. The software described in this document is provided under written license agreement, contains valuable trade secrets and proprietary information, and is protected by the copyright laws of the United States and other countries. It may not be copied or distributed in any form or medium, disclosed to third parties, or used in any manner not provided for in the software licenses agreement except with written prior approval from PTC.
  • European Biotechnology | Summer Edition | Vol

    European Biotechnology | Summer Edition | Vol

    I S S N 2 3 6 4 - 2 351 | A 6 0 711 | Interview Hospira’s Paul Greenland talks European about the launch Life Sciences and of the first mAb Industry Magazine biosimilar and the new challenges in Biotechnology Summer Edition 2015 | Volume 14 | 20 € development. Financing European biotech companies have added crowdinvesting to the fi nancing toolbox Nagoya Protocol Poor implementation of benefi t sharing could block Tracking biotech innovation in Europe Antibiotics New EU fi nancing instrument to close funding gap in high- stealthy risk antibiotic development EuroBioFairsCompass The unique guide to the top life killers sciences events in the second half of 2015 FREE EXCERPT Liquid Biopsy 4 CONTENTS European Biotechnology | Summer Edition | Vol. 14 | 2015 FREE EXCERPT COVER STORY INSIGHT EUROPE REGIONAL NEWS 6 European Commission opens 42 Northern Europe: fl oodgates for GM imports Sweden, Denmark, Finland, and Norway 10 First genome-edited crops to be stamped non-GMO by Member 44 Western Europe: States; Heard in Brussels France, Belgium, The Netherlands and the UK 12 European Commission and Euro- pean Investment Bank set to 46 Central Europe: launch new fi nancing instrument Austria, Germany and Switzerland for high-risk antibiotics develop- ment; Horizon2020 call focuses 48 Southern Europe: on personalised medicine; UK lags Italy, Spain, Portugal, Cyprus & Malta behind EU in fi ght against cancer; MEPs demand no dilution of EU life 50 Eastern Europe: sciences rules through TTIP Poland and the Czech Republic ECONOMY PICK & MIX 22 Interview: Paul
  • Como Prometió Fidel, En Junio Del 2001, Cuando Dijo: ¡Volverán!, Arribaron Hoy a Nuestra Patria, Gerardo, Ramón Y Antonio.” Raúl

    Como Prometió Fidel, En Junio Del 2001, Cuando Dijo: ¡Volverán!, Arribaron Hoy a Nuestra Patria, Gerardo, Ramón Y Antonio.” Raúl

    EDITOR: NOEL GONZÁLEZ GOTERA Nueva Serie. Número 166 Diseño: Lic. Roberto Chávez y Liuder Machado. Semana 131214 - 191214 Foto: Lic. Belkis Romeu e Instituto Finlay La Habana, Cuba. “Como prometió Fidel, en junio del 2001, cuando dijo: ¡Volverán!, arribaron hoy a nuestra Patria, Gerardo, Ramón y Antonio.” Raúl “Desde mi elección como Presidente de los Consejos de Estado y de Ministros, he reiterado en múltiples ocasiones, nuestra disposición a sostener con el gobierno de los Estados Unidos un diálogo respetuoso, basado en la igualdad soberana, para tratar los más diversos temas de forma recíproca, sin menoscabo a la independencia nacional y la autodeterminación de nuestro pueblo… Resultado de un diálogo al más alto nivel, que incluyó una conversación telefónica que sostuve ayer con el Presidente Barack Obama, se ha podido avanzar en la solución de algunos temas de interés para ambas naciones... Esta decisión del Presidente Obama, merece el respeto y reconocimiento de nuestro pueblo. … Proponemos al Gobierno de los Estados Unidos adoptar medidas mutuas para mejorar el clima bilateral y avanzar hacia la normalización de los vínculos entre nuestros países, basados en los principios del Derecho Internacional y la Carta de las Naciones Unidas… Cuba reitera su disposición a sostener cooperación en los organismos multilaterales, como la Organización de Naciones Unidas… Los progresos alcanzados en los intercambios sostenidos demuestran que es posible encontrar solución a muchos problemas… Como hemos repetido, debemos aprender el arte de convivir, de forma civilizada, con nuestras diferencias…“ Raúl Castro Ruz, La Habana, 17 de diciembre de 2014. Fragmentos de su alocución. 1 "Indeed, we've seen the benefits of cooperation between our countries before.
  • NASDAQ Stock Market LLC (“Nasdaq Exchange”), a Subsidiary of the Nasdaq Stock Market, Inc

    NASDAQ Stock Market LLC (“Nasdaq Exchange”), a Subsidiary of the Nasdaq Stock Market, Inc

    July 31, 2006 Nancy M. Morris, Esq. Secretary US Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 RE: Request for Relief from § 12 of the Securities Exchange Act of 1934 Dear Ms. Morris: On January 13, 2006, the Securities and Exchange Commission (“SEC” or “Commission”) approved the application of The NASDAQ Stock Market LLC (“Nasdaq Exchange”), a subsidiary of The Nasdaq Stock Market, Inc. (“Nasdaq”), to register under Section 6 of the Securities Exchange Act of 1934 (“Act” or “Exchange Act”) as a national securities exchange.1 Nasdaq’s transition of its listing and trading activities to the Nasdaq Exchange will further Congress’s instruction to promote “fair competition . between exchange markets.”2 Absent the relief requested herein, however, Nasdaq’s transition to a national securities exchange would require approximately 3,200 Nasdaq Global Market3 and Capital Market issuers with securities registered pursuant to the Act, or exempt from registration under Section 12(g) of the Act,4 to file registration statements5 to register those securities under Section 12(b) of the Act.6 1 Securities Exchange Act Release No. 53128 (January 13, 2006), 71 FR 3550 (January 23, 2006) (the “Exchange Approval Order”). 2 Exchange Act Section 11A(a)(1)(C)(ii). 3 Effective July 1, 2006, Nasdaq renamed the Nasdaq National Market as the Nasdaq Global Market and created a new segment within the Global Market called the Global Select Market. References to the Nasdaq Global Market include those securities listed on the Nasdaq Global Market and the Nasdaq Global Select Market. See Securities Exchange Act Release No.
  • Cancer Vaccine Therapies: Failures and Future Opportunities Michael D

    Cancer Vaccine Therapies: Failures and Future Opportunities Michael D

    Cancer Vaccine Therapies: Failures and Future Opportunities Michael D. Becker, Janet Dally, and Jeffrey Martini, Ph.D. Michael D. Becker President & CEO [email protected] Janet Dally Senior Vice President [email protected] Jeffrey Martini, Ph.D. Vice President [email protected] MD Becker Partners LLC 12 Penns Trail, #231 Newtown, PA 18940 Main phone: 267-756-7094 Email: [email protected] Web: www.mdbpartners.com www.mdbpartners.com Copyright © 2010 MD Becker Partners LLC All rights reserved MD Becker Partners LLC [This page intentionally left blank] Cancer Vaccine Therapies: Failures and Future Opportunities Page 2 MD Becker Partners LLC MD Becker Partners’ reports are limited publications that contain valuable information provided to a select group of customers. Our reports are for our customers’ internal use and not for general publication or disclosure to third parties. No part of this report may be given, lent, resold, or disclosed to non-customers without written permission. Furthermore, no part may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the permission of the publisher. For additional information, please refer to Appendix G: Legal Disclaimer. For information regarding permission, write: MD Becker Partners LLC 12 Penns Trail, #231 Newtown, PA 18940 Main phone: 267-756-7094 Email: [email protected] Web: www.mdbpartners.com MD Becker Partners is a boutique management and strategy consulting firm focusing on both public and private companies in the life sciences industry, including pharmaceuticals, biotechnology, and medical devices. We also work with venture capitalists, institutional investors, and others that provide capital to these companies.
  • Orphan Drug Dummy File

    Orphan Drug Dummy File

    Orphan Drug Designations and Approvals List as of 09‐01‐2016 Governs October 1, 2016 ‐ December 31, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 1 1. Prevention of secondary carnitine deficiency in valproic acid toxicity 2. Treatment of secondary carnitine deficiency in Sigma-Tau levocarnitine Carnitor 11/15/1989 valproic acid toxicity Pharmaceuticals, Inc. 2 1. Treatment of graft versus host disease in patients receiving bone marrow transplantation 2. Prevention of graft versus host disease in patients receiving Pediatric thalidomide n/a 9/19/1988 bone marrow transplantation Pharmaceuticals, Inc. 3 A Diagnostic for the management Advanced Imaging Theranost 68 Ga RGD n/a 10/1/2014 of Moyamoya disease (MMD) Projects, LLC (AIP) 4 Cadila heat killed Mycobacterium w Pharmaceuticals immunomodulator Cadi Mw 9/3/2004 Active tuberculosis Limited, Inc. 5 Adjunct to cytokine therapy in the treatment of acute myeloid Histamine Ceplene 12/15/1999 leukemia. EpiCept Corporation 6 Adjunct to surgery in cases of rh-microplasmin, ocriplasmin Jetrea 3/16/2004 pediatric vitrectomy ThromboGenics Inc. 7 Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or Ferring Laboratories, Somatostatin Zecnil 6/20/1988 pancreas. Inc. Page 1 of 377 Orphan Drug Designations and Approvals List as of 09‐01‐2016 Governs October 1, 2016 ‐ December 31, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 8 Adjunct to whole brain radiation therapy for the treatment of brain metastases in patients with Allos Therapeutics, efaproxiral n/a 7/28/2004 breast cancer Inc.
  • Rare Diseases, When Taken Together, Are Are Together, When Taken Diseases, Rare to According at All

    Rare Diseases, When Taken Together, Are Are Together, When Taken Diseases, Rare to According at All

    2013 MEDICINES IN DEVELOPMENT REPORT Rare Diseases A Report on Orphan Drugs in the Pipeline PRESENTED BY AMERICA’s biopharmACEUTICAL RESEARCH COMPANIES More Than 450 Medicines in Development for Rare Diseases Rare diseases, when taken together, are A major area of this research targets Orphan Drugs in Development* not that rare at all. In fact, according to rare cancers, accounting for more than Application the National Institutes of Health (NIH), one-third of all rare disease medicines in Submitted 30 million Americans have one of the development. Other top research areas Phase III nearly 7,000 diseases that are officially include genetic disorders, neurologi- Phase II deemed “rare” because alone they each cal conditions, infectious diseases and Phase I affect fewer than 200,000 people in autoimmune disorders. the United States. Sometimes, only Despite some recent victories, research a few hundred patients are known to 105 into treatments for rare diseases is a have a particular rare disease. daunting quest. This ongoing innovation Simply receiving a diagnosis of a rare and the hundreds of new medicines in disease often becomes a frustrating development now offer hope that physi- 85 quest, since many doctors may have nev- cians will have new treatment options er before heard of or seen the disease. for patients confronting a rare disease. This is, however, a time of great progress and hope. Biopharmaceutical 65 Contents research is entering an exciting new era Innovative Orphan Drugs with a growing understanding of the in the Pipeline ......................................... 2 human genome. Scientific advances have given researchers new tools to Orphan Drug Approvals ...........................4 explore rare diseases, which are often Challenges in Clinical Trials ......................6 more complex than common diseases.